<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00052442</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000258425</org_study_id>
    <secondary_id>MSKCC-02078</secondary_id>
    <secondary_id>NCI-H02-0100</secondary_id>
    <nct_id>NCT00052442</nct_id>
  </id_info>
  <brief_title>10-Propargyl-10-Deazaaminopterin in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma</brief_title>
  <official_title>A Phase II Study of 10-Propargyl-10-Deazaaminopterin (PDX) in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphomas and Hodgkin's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spectrum Pharmaceuticals, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Spectrum Pharmaceuticals, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of 10-propargyl-10-deazaaminopterin in&#xD;
      treating patients who have recurrent or refractory non-Hodgkin's lymphoma or Hodgkin's&#xD;
      lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the efficacy of 10-propargyl-10-deazaaminopterin, in terms of objective&#xD;
           response rate, duration of response, and time to disease progression, in patients with&#xD;
           relapsed or refractory aggressive non-Hodgkin's lymphoma or Hodgkin's lymphoma.&#xD;
&#xD;
        -  Determine the impact of pharmacokinetics on toxicity and drug elimination in patients&#xD;
           treated with this drug.&#xD;
&#xD;
        -  Determine the toxicity of this drug in these patients.&#xD;
&#xD;
        -  Determine the effect of prior chemotherapy response duration on duration of response in&#xD;
           patients treated with this drug.&#xD;
&#xD;
        -  Correlate, if possible, the pharmacodynamics (area under the curve) of this drug with&#xD;
           tumor response and toxicity (mucositis) in these patients.&#xD;
&#xD;
        -  Correlate, if possible, intraerythrocytic folate or homocysteine levels with severity of&#xD;
           mucositis in patients treated with this drug.&#xD;
&#xD;
        -  Determine whether levels of the RFC-1 folate transporter, folylpolyglutamate synthetase,&#xD;
           and folylpolyglutamate hydrolase are markers of response in patients treated with this&#xD;
           drug.&#xD;
&#xD;
      OUTLINE: This is an open-label study.&#xD;
&#xD;
      Patients receive 10-propargyl-10-deazaaminopterin IV over 1 hour on day 1. Courses repeat&#xD;
      every 14 days in the absence of disease progression or unacceptable toxicity. Patients&#xD;
      achieving a complete response (CR) may receive 2 additional courses beyond the CR.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 39-72 patients (12-35 for cohort 1 and 17-37 for cohort 2) will&#xD;
      be accrued for this study within 10-36 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2002</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response Rate</measure>
    <time_frame>3 weeks</time_frame>
    <description>Per Response Evaluation Criteria in T-cell and B-cell Lymphoma for target lesions and assessed using computerized tomography (CT) and or Positron emission tomography CT (PET CT) by local investigators: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=50% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicities of Pralatrexate</measure>
    <time_frame>3 weeks</time_frame>
    <description>Adverse events; number of patients with at least one adverse events reported.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>135 mg/m^2 Pralatrexate 1/2 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pralatrexate (PDX) 135 mg/m^2 administered as an intravenous (IV) infusion over one hour into a side arm of a running intravenous infusion of normal saline for 1/2 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>30 mg/m^2 Pralatrexate 3/4 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PDX 30 mg/m^2 administered as an IV infusion over 15 minutes into a side arm of a running intravenous infusion of normal saline for 3/4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>30 mg/m^2 Pralatrexate 6/7 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PDX 30 mg/m^2 administered as an IV infusion over 15 minutes into a side arm of a running intravenous infusion of normal saline for 6/7 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>45 mg/m^2 Pralatrexate 6/7 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PDX 45 mg/m^2 administered as an IV infusion over 15 minutes into a side arm of a running intravenous infusion of normal saline for 6/7 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>270 mg/m^2 Pralatrexate 2/4 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PDX (270 mg/m^2) administered as an IV bolus over 3-5 minutes into a side arm of a running intravenous infusion of normal saline for 2/4 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pralatrexate</intervention_name>
    <arm_group_label>135 mg/m^2 Pralatrexate 1/2 weeks</arm_group_label>
    <arm_group_label>270 mg/m^2 Pralatrexate 2/4 weeks</arm_group_label>
    <arm_group_label>30 mg/m^2 Pralatrexate 3/4 weeks</arm_group_label>
    <arm_group_label>30 mg/m^2 Pralatrexate 6/7 weeks</arm_group_label>
    <arm_group_label>45 mg/m^2 Pralatrexate 6/7 weeks</arm_group_label>
    <other_name>Folotyn</other_name>
    <other_name>10-Propargyl-10-Deazaaminopterin (PDX)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed Hodgkin's lymphoma or, using the World Health Organization&#xD;
             (WHO) classification, aggressive non-Hodgkin's lymphoma including:&#xD;
&#xD;
               -  Large B- or T-cell lymphomas (including transformed lymphomas)&#xD;
&#xD;
               -  Mantle cell lymphoma&#xD;
&#xD;
               -  Immunoblastic lymphoma&#xD;
&#xD;
          -  At least 1 unidimensionally measurable lesion&#xD;
&#xD;
               -  At least 2 centimeter (cm) by conventional techniques OR&#xD;
&#xD;
               -  At least 1 cm by spiral computerized tomography (CT) scan&#xD;
&#xD;
               -  Lymph nodes no greater than 1 cm in the short axis are considered normal&#xD;
&#xD;
          -  Relapsed or refractory disease after first-line chemotherapy&#xD;
&#xD;
          -  Cohort 1:&#xD;
&#xD;
               -  No more than 3 prior conventional cytotoxic chemotherapy regimens&#xD;
&#xD;
               -  Must have had at least a partial response (PR) lasting no more than 6 months or&#xD;
                  refractory disease&#xD;
&#xD;
               -  Patients with disease refractory to or relapsed less than 100 days from&#xD;
                  peripheral blood stem cell (PBSC) transplantation are not eligible&#xD;
&#xD;
          -  Cohort 2:&#xD;
&#xD;
               -  No limit on prior treatment&#xD;
&#xD;
               -  Must have had at least a PR to the last therapy lasting at least 6 months&#xD;
&#xD;
               -  Patients who have received high-dose chemotherapy as part of peripheral blood&#xD;
                  stem cells (PBSC) transplantation are eligible if relapse occurred at least 100&#xD;
                  days after transplantation&#xD;
&#xD;
          -  No clinically significant pleural effusions or ascites&#xD;
&#xD;
          -  No active brain or leptomeningeal metastases&#xD;
&#xD;
               -  Treated Central nervous system (CNS) disease allowed&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Karnofsky 70-100%&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count greater than 1,000/mm^3&#xD;
&#xD;
          -  Platelet count greater than 75,000/mm^3&#xD;
&#xD;
          -  Hemoglobin at least 10 g/dL&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin less than 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Aspartate aminotransferase/alanine aminotransferase (AST/ALT) no greater than 2.5&#xD;
             times ULN (4 times ULN if liver involvement)&#xD;
&#xD;
          -  Alkaline phosphatase no greater than 5 times ULN&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine no greater than 1.5 mg/dL OR&#xD;
&#xD;
          -  Creatinine clearance at least 50 mL/min&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No symptomatic congestive heart failure&#xD;
&#xD;
          -  No New York Heart Association class III or IV heart disease&#xD;
&#xD;
          -  No unstable angina pectoris&#xD;
&#xD;
          -  No cardiac arrhythmia&#xD;
&#xD;
          -  No myocardial infarction, cerebrovascular accident, or transient ischemic attack&#xD;
             within the past 6 months&#xD;
&#xD;
          -  No history of orthostatic hypotension&#xD;
&#xD;
          -  No ECG evidence of acute ischemia or significant conduction abnormality (e.g.,&#xD;
             bifascicular block or 2nd or 3rd degree atrioventricular blocks)&#xD;
&#xD;
          -  No uncontrolled hypertension requiring active manipulation of antihypertensive&#xD;
             medications&#xD;
&#xD;
          -  No grade III or IV edema&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No ongoing or active infection&#xD;
&#xD;
               -  Febrile episodes up to 38.5° Celsius without signs of active infection allowed&#xD;
&#xD;
          -  No other concurrent active cancer&#xD;
&#xD;
          -  No other concurrent serious medical illness&#xD;
&#xD;
          -  No psychiatric illness or social situation that would preclude study compliance&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 3 months since prior monoclonal antibody therapy (e.g., rituximab)&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  See Disease Characterisitics&#xD;
&#xD;
          -  At least 4 weeks since prior cytotoxic chemotherapy (6 weeks for mitomycin or&#xD;
             nitrosoureas) and recovered&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  At least 7 days since prior steroids&#xD;
&#xD;
          -  No concurrent steroids&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy and recovered&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  More than 4 weeks since prior major surgery&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No prior antifolates&#xD;
&#xD;
          -  No concurrent folic acid supplementation&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
&#xD;
          -  No concurrent combination antiretroviral therapy for human immunodeficiency virus&#xD;
             (HIV)-positive patients&#xD;
&#xD;
          -  No other concurrent investigational or commercial agents or therapies with the intent&#xD;
             to treat the malignancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Owen A. O'Connor, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>O'Connor OA, Horwitz S, Hamlin P, Portlock C, Moskowitz CH, Sarasohn D, Neylon E, Mastrella J, Hamelers R, Macgregor-Cortelli B, Patterson M, Seshan VE, Sirotnak F, Fleisher M, Mould DR, Saunders M, Zelenetz AD. Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies. J Clin Oncol. 2009 Sep 10;27(26):4357-64. doi: 10.1200/JCO.2008.20.8470. Epub 2009 Aug 3.</citation>
    <PMID>19652067</PMID>
  </results_reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>January 24, 2003</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <results_first_submitted>June 26, 2014</results_first_submitted>
  <results_first_submitted_qc>August 20, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">August 25, 2021</results_first_posted>
  <last_update_submitted>August 20, 2021</last_update_submitted>
  <last_update_submitted_qc>August 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
  <keyword>recurrent adult Burkitt lymphoma</keyword>
  <keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
  <keyword>recurrent adult lymphoblastic lymphoma</keyword>
  <keyword>recurrent mantle cell lymphoma</keyword>
  <keyword>recurrent adult Hodgkin lymphoma</keyword>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>10-deazaaminopterin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>135 mg/m^2 Pralatrexate 1/2 Weeks</title>
          <description>Pralatrexate 135 mg/m^2 administered as an IV infusion over one hour into a side arm of a running intravenous infusion of normal saline for 1/2 weeks.</description>
        </group>
        <group group_id="P2">
          <title>30 mg/m^2 Pralatrexate 3/4 Weeks</title>
          <description>Pralatrexate 30 mg/m^2 administered as an IV infusion over 15 minutes into a side arm of a running intravenous infusion of normal saline for 3/4 weeks.</description>
        </group>
        <group group_id="P3">
          <title>30 mg/m^2 Pralatrexate 6/7 Weeks</title>
          <description>Pralatrexate 30 mg/m^2 administered as an IV infusion over 15 minutes into a side arm of a running intravenous infusion of normal saline for 6/7 weeks.</description>
        </group>
        <group group_id="P4">
          <title>45 mg/m^2 Pralatrexate 6/7 Weeks</title>
          <description>Pralatrexate 45 mg/m^2 administered as an IV infusion over 15 minutes into a side arm of a running intravenous infusion of normal saline for 6/7 weeks.</description>
        </group>
        <group group_id="P5">
          <title>270 mg/m^2 Pralatrexate 2/4 Weeks</title>
          <description>Pralatrexate 270 mg/m^2 administered as an IV bolus over 3-5 minutes into a side arm of a running intravenous infusion of normal saline for 2/4 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="27"/>
                <participants group_id="P4" count="11"/>
                <participants group_id="P5" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="27"/>
                <participants group_id="P4" count="11"/>
                <participants group_id="P5" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety analysis population included all patients with at least one dose of pralatrexate.</population>
      <group_list>
        <group group_id="B1">
          <title>135 mg/m2 Pralatrexate 1/2 Weeks</title>
          <description>Pralatrexate 135 mg/m^2 administered as an IV infusion over one hour into a side arm of a running intravenous infusion of normal saline for 1/2 weeks.</description>
        </group>
        <group group_id="B2">
          <title>30 mg/m2 Pralatrexate 3/4 Weeks</title>
          <description>Pralatrexate 30 mg/m^2 administered as an IV infusion over 15 minutes into a side arm of a running intravenous infusion of normal saline for 3/4 weeks.</description>
        </group>
        <group group_id="B3">
          <title>30 mg/m2 Pralatrexate 6/7 Weeks</title>
          <description>Pralatrexate 30 mg/m^2 administered as an IV infusion over 15 minutes into a side arm of a running intravenous infusion of normal saline for 6/7 weeks.</description>
        </group>
        <group group_id="B4">
          <title>45 mg/m2 Pralatrexate 6/7 Weeks</title>
          <description>Pralatrexate 45 mg/m^2 administered as an IV infusion over 15 minutes into a side arm of a running intravenous infusion of normal saline for 6/7 weeks.</description>
        </group>
        <group group_id="B5">
          <title>270 mg/m2 Pralatrexate 2/4 Weeks</title>
          <description>Pralatrexate 270 mg/m^2 administered as an IV bolus over 3-5 minutes into a side arm of a running intravenous infusion of normal saline for 2/4 weeks.</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="27"/>
            <count group_id="B4" value="11"/>
            <count group_id="B5" value="15"/>
            <count group_id="B6" value="72"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.3" spread="16.1"/>
                    <measurement group_id="B2" value="54.3" spread="14.4"/>
                    <measurement group_id="B3" value="55.7" spread="16.5"/>
                    <measurement group_id="B4" value="52.7" spread="11.4"/>
                    <measurement group_id="B5" value="57.1" spread="15.1"/>
                    <measurement group_id="B6" value="54.1" spread="15.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="10"/>
                    <measurement group_id="B6" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="9"/>
                    <measurement group_id="B6" value="45"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Response Rate</title>
        <description>Per Response Evaluation Criteria in T-cell and B-cell Lymphoma for target lesions and assessed using computerized tomography (CT) and or Positron emission tomography CT (PET CT) by local investigators: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=50% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.</description>
        <time_frame>3 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>135 mg/m^2 Pralatrexate 1/2 Weeks</title>
            <description>Pralatrexate 135 mg/m^2 administered as an IV infusion over one hour into a side arm of a running intravenous infusion of normal saline for 1/2 weeks.</description>
          </group>
          <group group_id="O2">
            <title>30 mg/m^2 Pralatrexate 3/4 Weeks</title>
            <description>Pralatrexate 30 mg/m^2 administered as an IV infusion over 15 minutes into a side arm of a running intravenous infusion of normal saline for 3/4 weeks.</description>
          </group>
          <group group_id="O3">
            <title>30 mg/m^2 Pralatrexate 6/7 Weeks</title>
            <description>Pralatrexate 30 mg/m^2 administered as an IV infusion over 15 minutes into a side arm of a running intravenous infusion of normal saline for 6/7 weeks.</description>
          </group>
          <group group_id="O4">
            <title>45 mg/m^2 Pralatrexate 6/7 Weeks</title>
            <description>Pralatrexate 45 mg/m^2 administered as an IV infusion over 15 minutes into a side arm of a running intravenous infusion of normal saline for 6/7 weeks.</description>
          </group>
          <group group_id="O5">
            <title>270 mg/m^2 Pralatrexate 2/4 Weeks</title>
            <description>Pralatrexate 270 mg/m^2 administered as an IV bolus over 3-5 minutes into a side arm of a running intravenous infusion of normal saline for 2/4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Response Rate</title>
          <description>Per Response Evaluation Criteria in T-cell and B-cell Lymphoma for target lesions and assessed using computerized tomography (CT) and or Positron emission tomography CT (PET CT) by local investigators: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=50% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="11"/>
                <count group_id="O5" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="27"/>
                    <measurement group_id="O4" value="11"/>
                    <measurement group_id="O5" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Toxicities of Pralatrexate</title>
        <description>Adverse events; number of patients with at least one adverse events reported.</description>
        <time_frame>3 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>135 mg/m^2 Pralatrexate 1/2 Weeks</title>
            <description>Pralatrexate 135 mg/m^2 administered as an IV infusion over one hour into a side arm of a running intravenous infusion of normal saline for 1/2 weeks.</description>
          </group>
          <group group_id="O2">
            <title>30 mg/m^2 Pralatrexate 3/4 Weeks</title>
            <description>Pralatrexate 30 mg/m^2 administered as an IV infusion over 15 minutes into a side arm of a running intravenous infusion of normal saline for 3/4 weeks.</description>
          </group>
          <group group_id="O3">
            <title>30 mg/m^2 Pralatrexate 6/7 Weeks</title>
            <description>Pralatrexate 30 mg/m^2 administered as an IV infusion over 15 minutes into a side arm of a running intravenous infusion of normal saline for 6/7 weeks.</description>
          </group>
          <group group_id="O4">
            <title>45 mg/m^2 Pralatrexate 6/7 Weeks</title>
            <description>Pralatrexate 45 mg/m^2 administered as an IV infusion over 15 minutes into a side arm of a running intravenous infusion of normal saline for 6/7 weeks.</description>
          </group>
          <group group_id="O5">
            <title>270 mg/m^2 Pralatrexate 2/4 Weeks</title>
            <description>Pralatrexate 270 mg/m^2 administered as an IV bolus over 3-5 minutes into a side arm of a running intravenous infusion of normal saline for 2/4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Toxicities of Pralatrexate</title>
          <description>Adverse events; number of patients with at least one adverse events reported.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="11"/>
                <count group_id="O5" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="27"/>
                    <measurement group_id="O4" value="11"/>
                    <measurement group_id="O5" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>135 mg/m^2 Pralatrexate 1/2 Weeks</title>
          <description>Pralatrexate 135 mg/m^2 administered as an IV infusion over one hour into a side arm of a running intravenous infusion of normal saline for 1/2 weeks.</description>
        </group>
        <group group_id="E2">
          <title>30 mg/m^2 Pralatrexate 3/4 Weeks</title>
          <description>Pralatrexate 30 mg/m^2 administered as an IV infusion over 15 minutes into a side arm of a running intravenous infusion of normal saline for 3/4 weeks.</description>
        </group>
        <group group_id="E3">
          <title>30 mg/m^2 Pralatrexate 6/7 Weeks</title>
          <description>Pralatrexate 30 mg/m^2 administered as an IV infusion over 15 minutes into a side arm of a running intravenous infusion of normal saline for 6/7 weeks.</description>
        </group>
        <group group_id="E4">
          <title>45 mg/m^2 Pralatrexate 6/7 Weeks</title>
          <description>Pralatrexate 45 mg/m^2 administered as an IV infusion over 15 minutes into a side arm of a running intravenous infusion of normal saline for 6/7 weeks.</description>
        </group>
        <group group_id="E5">
          <title>270 mg/m^2 Pralatrexate 2/4 Weeks</title>
          <description>Pralatrexate 270 mg/m^2 administered as an IV bolus over 3-5 minutes into a side arm of a running intravenous infusion of normal saline for 2/4 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="11"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia &amp; Thrombocytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="11"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="11"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Vomitting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General Disorders</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Study completed</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Owen A. O'Connor, MD, PhD</name_or_title>
      <organization>Memorial Sloan-Kettering Cancer Center</organization>
      <phone>212-639-8889</phone>
      <email>oo2130@columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

